We are committed to serving the best interests of our shareholders. The investor pages that follow are your resource for financial information about Catalyst Biosciences, Inc.
NASDAQ: CBIO$9.241.27 (12.08%)Mar 30, 20174:00 p.m. ET
Delayed at least 15 minutes
Data provided by Nasdaq. Minimum 15 minutes delayed.
Press ReleasesMarch 28, 2017Catalyst Biosciences Announces IND Approval in South Korea for Next-Generation Subcutaneous Factor IX ProgramMarch 08, 2017Catalyst Biosciences Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate UpdateFebruary 16, 2017Catalyst Biosciences Announces Promotion of Andrew Hetherington to SVP of Technical OperationsView all press releases »
Reverse Stock Split
|For the 1 for 15 Reverse Stock Split Tax Form, click here|
Targacept Special Dividend
|For the FAQ and additional information, click here.|
Catalyst Biosciences, Inc.
Red House Consulting, LLC